The vaccine developed is a primate model and it is not ready to be used on humans.
This vaccine has vesicular stomatits virus that has a part of Ebola virus inserted into it. This virus then develops immune response against the Ebola Zaire.
The vaccine is created by an interdisciplinary team from the University of Texas Medical Branch at Galveston and Profectus BioSciences, Inc., it is undergoing testing in Galveston National Laboratory.
Thomas Geisbert, UTMB professor said that these new findings will help to develop a safer, single dose and efficient vaccine to fight Ebola outbreak.
The researchers have developed two next generation vaccines which are having weakened from of virus. Both these vaccines have ten-fold lower levels of virus in blood compared to the first generation vaccine.
The candidate vaccine has shown protection form a lethal amount of Makona strain of Ebola virus.
Both the weakened vaccines are having features of Mayinga strain of Ebola virus, as many other candidate Ebola Zaire vaccines are having.
The new West African Makona strain is similar to the 1976 Mayinga strain.
But it is important is test the vaccine to ensure that the small difference between the strains is not having any impact on the effectiveness of the vaccine.
The findings of the study are published in Nature.